



For Health Professionals Who Care For Cancer Patients

Inside This Issue:

- **Editor's Choice** – New Programs: Ibrutinib for Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma with 17p Deletion (ULYFIBRU)
- **Provincial Systemic Therapy Program** – Updated: Standards for Hazardous Drugs Manual
- **Benefit Drug List** – New: ULYFIBRU; Revised: [Class II to Class I Reclassification] – Bevacizumab: GICIRB, GICOXB, GIFFIRB, GIFFOXB, GOCXCATB; Capecitabine: BRAVCAP, BRAVDCAP, GIAJCAP, GIAJCAPOX, GIAVCAP, GIAVTZCAP, GICAPIRI, GICAPOX, GICART, GICIRB, GICOXB, GICPART, GIGAJCC, GIGAJCPRT, GIGAVCC, GIGAVECC, GIGECC, GIRAJCOX, GIRCAP, GIRCRT, GIRINFRT; Irinotecan: GIAVCETIR, GICAPIRI, GICIRB, GIFFIRB, GIFOLFIRI, GIGOLFIRI, GIIR, GIIRINALT, LUSCPI; Oxaliplatin: GICAPOX, GIAJCAPOX, GIAJFFOX, GICOXB, GIFFOXB, GIFOLFOX, GIHIPEC, GIRAJCOX, GIRAJFFOX
- **List of New and Revised Protocols, Provincial Pre-Printed Orders and Patient Handouts** – New: ULYFIBRU; Revised: BRAJDCARBT, BRAVABR, BRAVA7, GICOXB, GIFFOXB, UGIPGEMABR, ULYIBRU, MYBORMTN, MYBORPRE, UMYMPT
- **Website Resources and Contact Information**

EDITOR'S CHOICE

NEW PROGRAMS

The BCCA Provincial Systemic Therapy Program has approved the following new program effective 1 October 2016:

Lymphoma:

Ibrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Chromosome 17p Deletion (ULYFIBRU) – Ibrutinib was previously approved for the treatment of relapsed or refractory CLL/SLL in patients with or without 17p deletion (ULYIBRU). It is now approved for CLL/SLL patients with 17p deletion in the first-line setting based on a recent Health Canada approval for this indication. Clinical evidence in this patient population is limited in the first-line setting, and is primarily based on the benefit observed in those who have received at least one prior therapy.

PROVINCIAL SYSTEMIC THERAPY PROGRAM

UPDATED: STANDARDS FOR HAZARDOUS DRUGS MANUAL

The [BCCA Pharmacy Practice Standards for Hazardous Drugs Manual](#) has been updated in response to the recent publications from the U.S. Pharmacopeial Convention (USP) and the National Association of Pharmacy Regulatory Authorities (NAPRA).^{1,2} Updated modules within the manual are identified as “revised”, and updated content are highlighted in yellow. In addition, the BCCA Pharmacy Directives that have been affected by the updates are currently under revision.

Key updates include:

- Change from using non-sterile to sterile alcohol for disinfection in the cleanroom
- Removal of spray bottles from the cleanroom
- Introduction of the “controlled work area (CWA)” and the “demarcation line”
- New specifications on allowable wear time of chemotherapy gloves
- Clarification of jewelry, cosmetics and nail applications that must be removed when entering the CWA
- New requirement – wearing two pairs of shoe covers when entering the hazardous drug cleanroom
- New requirement – using disposable nail picks during hand hygiene procedure by sterile compounding personnel

Please see the [BCCA Pharmacy Practice Standards for Hazardous Drugs Manual](#) for further details about the above updates. Questions regarding these updates may be directed to the BCCA Pharmacy Oncology Certification Team at rxchemocert@bccancer.bc.ca.

References:

1. U.S. Pharmacopeial Convention (USP). February 2016 USP Compounding Compendium: General chapter <800> hazardous drugs – handling in healthcare settings. Rockville (MD); Feb 2016.
2. National Association of Pharmacy Regulatory Authorities (NAPRA). Model standards for pharmacy compounding of non-hazardous sterile preparations [Internet]. Ottawa (ON): The NAPRA; Nov 2015. Available from: http://napra.ca/pages/Practice_Resources/pharmacy_compounding.aspx.

BENEFIT DRUG LIST

NEW PROGRAMS

Effective 1 October 2016, the following BCCA treatment program has been added to the BCCA [Benefit Drug List](#):

Protocol Title	Protocol Code	Benefit Status
Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma with Chromosome 17p Deletion Using iBRUtinib	ULYFIBRU	Restricted

BENEFIT DRUG LIST

REVISED PROGRAMS

Effective 1 October 2016, the following BCCA treatment programs have been reclassified from **Class II** to **Class I** status on the BCCA [Benefit Drug List](#):

Drug	Tumour Site	Protocol Title	Protocol Code
Bevacizumab	Gastrointestinal	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Irinotecan, Bevacizumab and Capecitabine	GICIRB
		Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Oxaliplatin, Bevacizumab and Capecitabine	GICOXB
		Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Irinotecan, Fluorouracil, Leucovorin and Bevacizumab	GIFFIRB
		Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Oxaliplatin, Fluorouracil, Leucovorin and Bevacizumab	GIFFOX
	Gynecology	Primary Treatment of Metastatic or Recurrent Squamous Cancer of the Cervix with Bevacizumab, CARBOplatin and PACLitaxel	GOCXCATB
Capecitabine	Breast	Therapy for Metastatic Breast Cancer Using Capecitabine	BRAVCAP
		Palliative Therapy for Metastatic Breast Cancer Using DOCEtaxel and Capecitabine	BRAVDCAP
	Gastrointestinal	Adjuvant Therapy of Colon Cancer Using Capecitabine	GIAJCAP
		Adjuvant Combination Chemotherapy for Stage III and Stage IIB Colon Cancer Using Oxaliplatin and Capecitabine	GIAJCAPOX
		Palliative Therapy of Advanced Colorectal Cancer using Capecitabine	GIAVCAP
		Palliative Therapy of Metastatic Neuroendocrine Cancer Using Temozolomide and Capecitabine	GIAVTZCAP
		Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Irinotecan and Capecitabine in Patients Unsuited for GIFOLFIRI	GICAPIRI
		Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Oxaliplatin and Capecitabine	GICAPOX
		Combined Modality Therapy for Carcinoma of the Anal Canal Using Mitomycin, Capecitabine and Radiation Therapy	GICART
		Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Irinotecan, Bevacizumab and Capecitabine	GICIRB
		Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Oxaliplatin, Bevacizumab and Capecitabine	GICOXB
		Combined Modality Therapy for Carcinoma of the Anal Canal Using CISplatin, Capecitabine and Radiation Therapy	GICPART
		Adjuvant Chemotherapy of Gastric Cancer Patients with D2 Resection (Node Negative) or Ineligible for Adjuvant Chemoradiation, Using CISplatin and Capecitabine	GIGAJCC
		Adjuvant Chemotherapy of Gastric Cancer Patients with Completely Resected Gastric Cancer Using CISplatin and Capecitabine and Radiation Therapy	GIGAJCPT
		Palliative Therapy for Metastatic or Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Using CISplatin and Capecitabine	GIGAVCC
Palliative Therapy for Metastatic or Locally Advanced Gastric or Esophagogastric Cancer Using Epirubicin, CISplatin and Capecitabine	GIGAVECC		

BENEFIT DRUG LIST

Drug	Tumour Site	Protocol Title	Protocol Code
Capecitabine (continued)	Gastrointestinal (continued)	Perioperative Treatment of Resectable Adenocarcinoma of the Stomach, Gastroesophageal Junction or Lower 1/3 Esophagus Using Epirubicin, CISplatin and Capecitabine	GIGECC
		Adjuvant Combination Chemotherapy for Stage III Rectal Cancer Using Oxaliplatin and Capecitabine	GIRAJCOX
		Adjuvant Therapy for Stage II and III Rectal Cancer Previously Treated with Preoperative Radiation Therapy using Capecitabine	GIRCAP
		Combined Modality Adjuvant Therapy for High Risk Rectal Carcinoma Using Capecitabine and Radiation Therapy	GIRCRT
		Combined Modality Adjuvant Therapy for High Risk Rectal Carcinoma Using Capecitabine, Infusional Fluorouracil and Radiation Therapy	GIRINFRT
Irinotecan	Gastrointestinal	Third-Line Treatment of Metastatic Colorectal Cancer Using Cetuximab in Combination with Irinotecan	GIAVCETIR
		Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Irinotecan and Capecitabine in Patients Unsuitable for GIFOLFIRI	GICAPIRI
		Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Irinotecan, Bevacizumab and Capecitabine	GICIRB
		Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Irinotecan, Fluorouracil, Leucovorin and Bevacizumab	GIFFIRB
		Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Irinotecan, Fluorouracil and Leucovorin	GIFOLFIRI
		Palliative Combination Chemotherapy for Metastatic Gastric or Esophageal Adenocarcinoma Using Irinotecan, Fluorouracil and Leucovorin	GIGOLFIRI
		First- or Second-Line Palliative Chemotherapy for Metastatic Colorectal Cancer Using Irinotecan	GIIR
		Second-Line Treatment for Fluorouracil Refractory Metastatic Colorectal Cancer Using Weekly Scheduled Irinotecan	GIIRINALT
		Second-Line Treatment of Extensive Stage Small Cell Lung Cancer (SCLC) with Irinotecan with or without Platinum	LUSCPI
	Oxaliplatin	Gastrointestinal	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Oxaliplatin and Capecitabine
Adjuvant Combination Chemotherapy for Stage III and Stage IIB Colon Cancer Using Oxaliplatin and Capecitabine			GIAJCAPOX
Adjuvant Combination Chemotherapy for Stage III and Stage IIB Colon Cancer Using Oxaliplatin, Fluorouracil and Leucovorin			GIAJFFOX
Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Oxaliplatin, Bevacizumab and Capecitabine			GICOXB
Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Oxaliplatin, Fluorouracil, Leucovorin and Bevacizumab			GIFFOX B
Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Oxaliplatin, Fluorouracil and Leucovorin			GIFOLFOX
Hyperthermic Intraperitoneal Chemotherapy for Patients with Peritoneal Carcinomatosis from Limited Advanced Colorectal and Appendiceal Carcinomas Using Oxaliplatin and Fluorouracil			GIHIPEC
Adjuvant Combination Chemotherapy for Stage III Rectal Cancer Using Oxaliplatin and Capecitabine			GIRAJCOX
Adjuvant Combination Chemotherapy for Stage III Rectal Cancer Using Oxaliplatin, Fluorouracil and Leucovorin			GIRAJFFOX

LIST OF NEW AND REVISED PROTOCOLS, PRE-PRINTED ORDERS AND PATIENT HANDOUTS

BC Cancer Agency Protocol Summaries, Provincial Pre-Printed Orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below. Protocol codes for treatment requiring BCCA Compassionate Access Program approval are prefixed with the letter “U”.

NEW PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)

CODE	Protocol	PPPO	Patient Handout	Protocol Title
ULYFIBRU	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma with Chromosome 17p Deletion Using iBRUtinib

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
BRAJDCARBT	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Typo corrected under BCCA Administration Guideline for docetaxel</i>	Adjuvant Therapy for Breast Cancer Using DOCEtaxel, CARBOplatin, and Trastuzumab (HERCEPTIN®)
BRAVABR	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Administration device clarified</i>	Palliative Therapy for Metastatic Breast Cancer Using Nanoparticle, Albumin-Bound (Nab)-PACLitaxel (ABRAXANE®)
BRAVA7	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Contact Physician updated</i>	Palliative Therapy for Metastatic Breast Cancer using Weekly DOXOrubicin
GICOXB	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>IV priming line clarified</i>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Oxaliplatin, Bevacizumab and Capecitabine
GIFFOX B	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>IV priming line clarified</i>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Oxaliplatin, Fluorouracil, Leucovorin and Bevacizumab
UGIPGEMABR	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Administration device clarified</i>	First-Line Treatment of Locally Advanced and Metastatic Pancreatic Cancer with PACLitaxel-Nab (ABRAXANE®) and Gemcitabine
ULYIBRU	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Treatment duration clarified</i>	Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Using iBRUtinib
MYBORMTN	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility clarified</i>	Maintenance Therapy of Multiple Myeloma Using Bortezomib for Patients with the High-Risk Chromosome Abnormality

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
MYBORPRE	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility clarified</i>	Treatment of Multiple Myeloma Using Bortezomib, Dexamethasone with or without Cyclophosphamide as Induction Pre-Stem Cell Transplant
UMYMPT	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Eligibility clarified</i>	Treatment of Multiple Myeloma Using Melphalan, Prednisone and Thalidomide

WEBSITE RESOURCES AND CONTACT INFORMATION

WEBSITE RESOURCES	WWW.BCCANCER.BC.CA
Systemic Therapy Update	www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy/systemic-therapy-update
Reimbursement & Forms: Benefit Drug List, Class II, Compassionate Access Program	www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy
Cancer Drug Manual	www.bccancer.bc.ca/health-professionals/professional-resources/cancer-drug-manual
Cancer Management Guidelines	www.bccancer.bc.ca/health-professionals/professional-resources/cancer-management-guidelines
Cancer Chemotherapy Protocols, Pre-Printed Orders, Protocol Patient Handouts	www.bccancer.bc.ca/health-professionals/professional-resources/chemotherapy-protocols
Systemic Therapy Program Policies	www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy
CON Pharmacy Educators	www.bccancer.bc.ca/health-professionals/professional-resources/pharmacy

CONTACT INFORMATION	PHONE	FAX	EMAIL
Systemic Therapy Update Editor			bulletin@bccancer.bc.ca
Provincial Systemic Therapy Program	604-877-6000 x 672247		mclin@bccancer.bc.ca
To update contact information of any CON sites, please contact:			bulletin@bccancer.bc.ca
Oncology Drug Information	604-877-6275		druginfo@bccancer.bc.ca
Education Resource Nurse	604-877-6000 x 672638		nursinged@bccancer.bc.ca
Library/Cancer Information	604-675-8003 Toll Free 888-675-8001 x 8003		requests@bccancer.bc.ca
Pharmacy Professional Practice	604-877-6000 x 672247		mclin@bccancer.bc.ca
Nursing Professional Practice	604-877-6000 x 672623		ilundie@bccancer.bc.ca
OSCAR	888-355-0355	604-708-2051	oscar@bccancer.bc.ca
Compassionate Access Program (CAP)	604-877-6277	604-708-2026	cap_bcca@bccancer.bc.ca
Pharmacy Chemotherapy Certification	250-712-3900 x 686741		rxchemocert@bccancer.bc.ca
BCCA-Abbotsford Centre	604-851-4710 Toll Free 877-547-3777		
BCCA-Centre for the North	250-645-7300 Toll Free 888-775-7300		
BCCA-Fraser Valley Centre	604-930-2098 Toll Free 800-523-2885		
BCCA-Sindi Ahluwalia Hawkins Centre for the Southern Interior	250-712-3900 Toll Free 888-563-7773		
BCCA-Vancouver Centre	604-877-6000 Toll Free 800-663-3333		
BCCA-Vancouver Island Centre	250-519-5500 Toll Free 800-670-3322		

EDITORIAL REVIEW BOARD

Sally Waignein, PharmD (Editor)
 Mario de Lemos, PharmD, MSc (Oncol)
 Caroline Lohrisch, MD
 Robert Crisp, BScPT, MBA

Lorraine Leitz, MLS
 Ava Hatcher, RN, BN CONc
 Rob Watt, BSc(Pharm)